Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael Siu-Nam Wong has a total of 49 co-authors. Here are the top co-authors by number of shared publications:

  • Adhitya Logan

    Henry E. Riggs School of Applied Life Sciences, Keck Graduate Institute, Claremont, California 91711, United States

    1 shared publication
  • Anastasia Levitin

    Henry E. Riggs School of Applied Life Sciences, Keck Graduate Institute, Claremont, California 91711, United States

    1 shared publication
  • Aya El Helali

    Department of Clinical Oncology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China

    1 shared publication
  • Bryan Ho-Kwan Yun

    Department of Clinical Oncology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China

    1 shared publication
  • Carlos King Ho Wong

    Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine The University of Hong Kong Hong Kong SAR China

    1 shared publication
  • Cheng-Vai Hui

    Department of Clinical Oncology, Centro Hospitalar Conde de São Januário, Macao SAR, China

    1 shared publication

Latest Publications

  • Open Access

    Adjuvant Chemotherapy in Older Patients with Gastric Cancer: A Population-Based Cohort Study

    by Wing-Lok Chan, Xiaodong Liu, Carlos King-Ho Wong, Michael Siu-Nam Wong, Ian Yu-Hong Wong, Ka-On Lam, Bryan Ho-Kwan Yun, Emina Edith Cheung, Rosa Pui-Ying Tse, Fion Chan, et al.

    (1) Background: The effectiveness of adjuvant chemotherapy in older patients with gastric cancer after D2-gastrectomy is unclear. This study investigated the efficacy of adjuvant chemotherapy in elderly patients with stage II/III gastric cancer. (2) Methods: A real-world population-based retrospective cohort of patients aged ≥65 with stage II/III gastric cancer (n = 2616; median age: 73.5; 12.2% aged >80 years) treated between 1 January 1997 and 31 December 2020 were included. All data was retrieved from the Hong Kong Hospital Authority Clinical Management System (CMS). Clinical characteristics of those patients with and without adjuvant chemotherapy treatment were balanced after propensity score matching (PSM). In total, 732 patients treated with adjuvant chemotherapy were matched with 732 patients treated with surgery alone. Hazard ratios (HRs) estimated via Cox proportional hazards regression models were used to compare the overall survival (OS) and cancer-specific survival (CSS) of the two patient groups. (3) Results: Adjuvant chemotherapy was associated with better OS (37 vs. 25 months; HR: 0.80; 95% CI: 0.75–0.84; p < 0.001) than surgery alone. The OS benefit was observed in both the 65–80 (44 vs. 27 months; HR: 0.79; 95% CI: 0.74–0.84; p < 0.001) and >80 (14 vs. 11 months; HR: 0.82; 95% CI: 0.71–0.96; p < 0.001) age groups. A better CSS was observed in patients who received adjuvant chemotherapy than those who only had surgery (5-year CSS: 64.1% vs. 61.1%, HR: 0.85; 95% CI: 0.79–0.93; p < 0.001). (4) Conclusions: adjuvant chemotherapy significantly improved OS and CSS in older patients with stage II/III gastric cancer.


  • Open Access

    Consensus Statements on Precision Oncology in the China Greater Bay Area

    by Tai-Chung Lam, William Chi-Shing Cho, Joseph Siu-Kie Au, Edmond Shiu-Kwan Ma, Stephen Tak-Sum Lam, Herbert Ho-Fung Loong, Jason Wing Hon Wong, S. N. Michael Wong, S.N. Michael Wong, Victor Ho-Fun Lee, et al.

    BACKGROUND: Next-generation sequencing comprehensive genomic panels (NGS CGPs) have enabled the delivery of tailor-made therapeutic approaches to improve survival outcomes in patients with cancer. Within the China Greater Bay Area (GBA), territorial differences in clinical practices and health care systems and strengthening collaboration warrant a regional consensus to consolidate the development and integration of precision oncology (PO). Therefore, the Precision Oncology Working Group (POWG) formulated standardized principles for the clinical application of molecular profiling, interpretation of genomic alterations, and alignment of actionable mutations with sequence-directed therapy to deliver clinical services of excellence and evidence-based care to patients with cancer in the China GBA. METHODS: Thirty experts used a modified Delphi method. The evidence extracted to support the statements was graded according to the GRADE system and reported according to the Revised Standards for Quality Improvement Reporting Excellence guidelines, version 2.0. RESULTS: The POWG reached consensus in six key statements: harmonization of reporting and quality assurance of NGS; molecular tumor board and clinical decision support systems for PO; education and training; research and real-world data collection, patient engagement, regulations, and financial reimbursement of PO treatment strategies; and clinical recommendations and implementation of PO in clinical practice. CONCLUSION: POWG consensus statements standardize the clinical application of NGS CGPs, streamline the interpretation of clinically significant genomic alterations, and align actionable mutations with sequence-directed therapies. The POWG consensus statements may harmonize the utility and delivery of PO in China's GBA.


  • Identification of Bithionol, Dichlorophen, and Miconazole as Antibacterial Agents against Acinetobacter calcoaceticus

    by Tiffany H. Khaw, S.N. Michael Wong, Genevieve Herle, Jean Patrick Gonzalez Dahua, Adhitya Logan, Saleem Alameh, Mikhail Martchenko Shilman, Anastasia Levitin

    The rising prevalence of multidrug-resistant hospital-acquired infections has increased the need for new antibacterial agents. In this study, a library of 1586 FDA-approved drugs was screened against A. calcoaceticus, a representative of the Acinetobacter calcoaceticus–baumannii complex. Three compounds were found to have previously undiscovered antibacterial properties against A. calcoaceticus: antifungal Miconazole, anthelminthic Dichlorophen, and Bithionol. These three drugs were tested against a wide range of Gram-positive and Gram-negative bacteria and confirmed to have broad-spectrum antibacterial properties. Combinations of these three drugs were also tested against the same bacteria, and two novel combination therapies with synergistic effects were discovered. In the future, antibacterial properties of these three drugs and two combination therapies will be evaluated against pathogenic bacteria using an animal model.